SCHEMBL626679

SCHEMBL626679

NC(=O)[C@H](N)CN(c1ccccc1)c1ncccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPI P09923 1/20 0.35
PKM P14618 1/20 0.35
PTGS1 P23219 1/20 0.35
XIAP P98170 1/20 0.35
SLC7A5 Q01650 1/20 0.35
KCNH2 Q12809 2/20 0.35
IKBKB O14920 1/20 0.34
KMT2A Q03164 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
PTPRA P18433 1/20 0.34
LTA4H P09960 3/20 0.33
SLC1A5 Q15758 2/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
AGER Q15109 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626690 1.00 ALPI (0.35) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL626680 1.00 ALPI (0.35) ALPIPKMPTGS1XIAPSLC7A5
Water SCHEMBL15012752 0.98 ALPI (0.34) ALPIPKMPTGS1XIAPSLC7A5
Water SCHEMBL15012669 0.98 ALPI (0.34) ALPIPKMPTGS1XIAPSLC7A5
Water SCHEMBL15012398 0.98 ALPI (0.34) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL2836743 0.87 ALPI (0.41) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL2704117 0.87 FFAR1 (0.43) IKBKBKMT2APOLBTSHRFFAR1
SCHEMBL15012267 0.82 LTA4H (0.45) IKBKBKMT2AMTNR1AMTNR1BLTA4H
SCHEMBL15012266 0.82 LTA4H (0.45) IKBKBKMT2AMTNR1AMTNR1BLTA4H
SCHEMBL15012672 0.82 LTA4H (0.45) IKBKBKMT2AMTNR1AMTNR1BLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877926-B2 Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives SANOFI (FR) 2014-11-04 US claimed
EP-2603491-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI SA (FR) 2014-09-24 EP claimed
US-20130211085-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2013-08-15 US claimed
EP-2603491-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2013-06-19 EP claimed
WO-2012019967-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2012-02-16 WO claimed
US-9434696-B2 Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives SANOFI (FR) 2016-09-06 US disclosed
US-9434696-B2 Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives SANOFI (FR) 2016-09-06 US disclosed
US-9434696-B2 Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives SANOFI (FR) 2016-09-06 US disclosed
US-8877926-B2 Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives SANOFI (FR) 2014-11-04 US disclosed
US-8877926-B2 Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives SANOFI (FR) 2014-11-04 US disclosed
US-8877926-B2 Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives SANOFI (FR) 2014-11-04 US disclosed
EP-2603491-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI SA (FR) 2014-09-24 EP disclosed
EP-2603491-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI SA (FR) 2014-09-24 EP disclosed
US-20130211085-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2013-08-15 US disclosed
US-20130211085-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2013-08-15 US disclosed
US-20130211085-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2013-08-15 US disclosed
EP-2603491-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2013-06-19 EP disclosed
WO-2012019967-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2012-02-16 WO disclosed
WO-2012019967-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES SANOFI (FR) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211085-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES C9, DDT, IDUA ALPI 3968/4885PKM 2991/4885PTGS1 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.